Elite in Pulmonary Embolism

Laurent Bertoletti

Saint-etienne-de-valoux, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Pulmonary Embolism
Saint-etienne-de-valoux, FR 
OverviewLocationsClinical Research

Overview

Laurent Bertoletti practices in Saint-etienne-de-valoux, France. Mr. Bertoletti is rated as an Elite expert by MediFind in the treatment of Pulmonary Embolism. His top areas of expertise are Pulmonary Embolism, Venous Thromboembolism (VTE), Mesenteric Venous Thrombosis, Thrombectomy, and Angioplasty.

His clinical research consists of co-authoring 282 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 101 articles and participated in 5 clinical trials in the study of Pulmonary Embolism.

Gender
Male

Locations

Saint-etienne-de-valoux, France
Other Locations
Saint Étienne, France
Saint-jean-saint-germain, 42055, France
Saint-priest-la-vetre, France
CHU De St Étienne, Saint-etienne, 42055, France
Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Impact on Quality of Life with Pulmonary RehAbilitation After Pulmonary EMBOlism: RAMBO Study
Impact on Quality of Life with Pulmonary RehAbilitation After Pulmonary EMBOlism: RAMBO Study
Enrollment Status: Recruiting
Publish Date: December 16, 2024
Intervention Type: Other
Study Phase: Not Applicable
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension : HEMA-HTP Multicentric Study.
Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension : HEMA-HTP Multicentric Study.
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Cancer Associated Thrombosis: What is the Proportion of Patients Ineligible to a Study as CARAVAGGIO (a Retrospective Multicenter Study)
Cancer Associated Thrombosis: What is the Proportion of Patients Ineligible to a Study as CARAVAGGIO (a Retrospective Multicenter Study)
Enrollment Status: Completed
Publish Date: October 11, 2023
Intervention Type: Other
Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Enrollment Status: Completed
Publish Date: December 05, 2022
Intervention Type: Drug
Study Phase: Phase 1
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Enrollment Status: Terminated
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drugs: Apixaban, Rivaroxaban, Heparin, VKA
Study Phase: Phase 3
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Enrollment Status: Completed
Publish Date: August 25, 2022
Intervention Type: Other
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 3
Clinical Echography in Emergency Prognostic Evaluation of Pulmonary Embolism: ECU -EP Study.
Clinical Echography in Emergency Prognostic Evaluation of Pulmonary Embolism: ECU -EP Study.
Enrollment Status: Withdrawn
Publish Date: April 04, 2019
Intervention Type: Procedure
Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Enrollment Status: Completed
Publish Date: December 29, 2017
Intervention Type: Other
Study Phase: Not Applicable
Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?
Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?
Enrollment Status: Completed
Publish Date: January 23, 2017
Intervention Type: Other
View 12 Less Clinical Trials

282 Total Publications

Prevention of venous thromboembolism in critically ill patients: current state and future perspectives.
Prevention of venous thromboembolism in critically ill patients: current state and future perspectives.
Journal: European journal of internal medicine
Published: October 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bertoletti's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile